Asthma and COPD Devices Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Asthma and COPD Devices Market is segmented By Product (Inhalers, Nebulizers), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Asthma and COPD Devices Market Overview

Global Asthma and COPD Devices Market reached US$ 41.2 billion in 2022 and is expected to reach US$ 61.2 billion by 2030 growing with a CAGR of 4.5% during the forecast period 2023-2030.

Asthma causes inflammation and swelling of the airways and it results in narrowing of the airways that carry oxygen to the lungs. Asthma and Chronic Obstructive Pulmonary Disease (COPD) are treated with handheld inhalers that deliver medicine directly to the lungs through the mouth. Types of inhaler devices include pressurized metered dose inhalers, dry powder inhalers, and soft mist inhalers.

Furthermore, significant growth drivers such as increasing technological advancements, product launches, and rising awareness for asthma and COPD give rise to future market growth. Significant key players like GlaxoSmithKline Plc., Novartis AG, AstraZeneca Plc., Pfizer Inc., Lepu Medical Technology Co. Ltd., and others are actively operating in the market.

Asthma and COPD Devices Marke Scope

For more details on this report Request for Sample

Asthma and COPD Devices Market Dynamics

Increasing Product Launches for Asthma and COPD Devices

Inhalers and nebulizers are the two main ways inhaled medicine is used to treat asthma and COPD. The product launches by major companies help to drive market growth and these effective research and developments help in product launches and also finding new treatments and improve care for millions of people with asthma and COPD conditions.

For instance, in August 2023, Viatris and Kindeva Drug Delivery LP launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca’s Symbicort. Breyna is a drug-device combination product that is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). It is indicated for asthma patients of 6 years and above.

Additionally, in May 2022, in line with the theme of World Asthma Day “ Closing Gaps In Asthma Carte”, Alkem Laboratories launched Innohaler, a DPI device to make life easier for Asthma and COPD patients. Hence, due to the above factors, the market is expected to boost over the forecast period.

Rising Awareness for Asthma and COPD is Boosting the Asthma and COPD Devices Market

The global asthma and COPD devices market has witnessed significant growth in recent years due to the rising awareness of asthma and COPD conditions. Awareness conducted by government and private organizations for asthma and COPD helps people understand the risks of smoking and chemical exposure. It also helps people with symptoms to seek treatment earlier and could even improve a person's life expectancy.

For instance, in April 2022, VillageMD and the COPD Foundation declared a partnership to better identify and treat chronic obstructive pulmonary disease (COPD) at Village Medical practices. This partnership aims to raise awareness through education and outreach campaigns to patients help identify those with undiagnosed COPD, and increase access to pulmonary rehabilitation.

Additionally, in May 2020, The Florida Department of Health recognizes May as National Asthma Awareness Month and takes the opportunity to educate Floridians regarding diagnosis and treatment programs committed to improving the lives of those living with asthma. The department is working with national and statewide partners to make life better for Floridians with asthma and their families by promoting the use of a tailored, written asthma action plan (AAP) as part of a comprehensive approach to asthma care.

Side Effects Associated with Nebulizer Will Hamper the Growth of the Market 

Side effects of using a nebulizer include allergic reactions such as skin rash, itching, hives, and swelling of the face, lips, tongue, or throat. It can also lead to heart rhythm changes, fast or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, and trouble breathing. Using of nebulizer can also increase blood pressure and cause muscle cramps or pain. Thus, the above factors are expected to hamper the market growth.

Asthma and COPD Devices Marke Segment Analysis

The global asthma and COPD devices market is segmented based on product, distribution channel, and region.

Inhalers from the Product Segment Accounted for Approximately XX% of the Global Asthma and COPD Devices Market Share 

Asthma inhalers are hand-held, portable devices that deliver medication to the lungs. Doctors suggest the use of inhaled corticosteroids (ICS) to prevent asthma symptoms along with a rescue inhaler for quick relief of attacks. Inhalers are expected to hold the largest market share over the period forecast owing to increasing product launches.

For instance, in July 2023, Teva UK launched a new GoResp Digihaler system in the United Kingdom. GoResp Digihaler is the first integrated inhaler device with built-in sensors that detect and record objective data on the patient’s use and ability to use their inhaler including inspiratory flow classification. 

Additionally, in July 2023,  Hormosan Pharma GmbH, a wholly-owned subsidiary of the Lupin company in Germany, launched Luforbec, a pressurized metered dose inhaler in the European nation. Luforbec is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist is suitable.

Asthma and COPD Devices Marke Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022

The global asthma and COPD devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the asthma and COPD devices market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence and incidence of asthma conditions, and product approvals in asthma and COPD devices.

For instance, according to the Asthma and Allergy Foundation of America 2023, nearly 26 million people in the U.S. have asthma and this equals about 1 in 13 people. Nearly 21 million U.S. adults ages 18 and older have asthma. Asthma is more common in female adults than in male adults. Around 9.7% of female adults have asthma, compared to 6.2% of male adults. 

Additionally, in January 2023, Airsupra (albuterol/budesonide) was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide.

Competitive Landscape

The major global players in the market include GlaxoSmithKline Plc., Novartis AG, AstraZeneca Plc., Pfizer Inc., Lepu Medical Technology Co. Ltd., Omron Healthcare Co. Ltd., Trudell Medical International, Beurer GmbH, Merck KGaA, PARI GmbH among others.

COVID-19 Impact Analysis On Asthma and COPD Devices Marke

The COVID-19 pandemic has had a significant impact on the global asthma and COPD devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device launches, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduces asthma and COPD diagnoses in many patients suffering from these chronic diseases. 

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the asthma and COPD devices market is expected to be moderately affected over the forecast period.

Key Developments

• In January 2023, Synergy Life Science, Inc. developed Nebi which is the first pocket-sized and fully battery-operated nebulizer for use in a variety of applications. Nebi is powered by a rechargeable battery and is small enough to fit into a pocket or purse allowing easy access to nebulizer therapies.
• In February 2023, Aptar Pharma, launched the HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device. HeroTracker Sense is a next-generation metered-dose inhaler (MDI) add-on connected device, designed to address patient inhalation technique and adherence.
• In May 2023, South Africa by the Allergy Foundation of South Africa (AFSA) launched a new device called the AfriSpacer which makes inhalation of medication from an asthma pump easier and far more effective. 

Why Purchase the Report?

• To visualize the global asthma and COPD devices market segmentation based on product, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of global asthma and COPD devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global asthma and COPD devices market report would provide approximately 69 tables, 70 figures, and 195 Pages.